Form 4: Nevro Corp. Director D. Keith Grossman Reports Disposition of Shares in Globus Medical Merger

D. Keith Grossman, a director of Nevro Corp., reported the disposition of 228,552 shares of common stock due to the merger with Globus Medical, Inc., where each share was converted into the right to receive $5.85 in cash.

Summary

• D. Keith Grossman, a director of Nevro Corp., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the disposition of 228,552 shares of Nevro Corp. common stock on April 3, 2025.
• This disposition is a result of the merger between Nevro Corp. and Globus Medical, Inc., which became effective on April 3, 2025.
• As part of the merger agreement, each outstanding share of Nevro Corp. common stock was converted into the right to receive $5.85 in cash.
• Outstanding restricted stock units and performance stock units were also converted into the right to receive cash based on the merger consideration.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to a merger. It doesn't convey strong positive or negative sentiment, but rather reports a factual event. The sentiment is neutral.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a consolidation trend in the medical device industry, where larger companies acquire smaller, specialized firms to expand their product portfolios and market reach. Globus Medical's acquisition of Nevro Corp. is likely aimed at strengthening its position in the neuromodulation market.

Comparison to Industry Standards

• Mergers and acquisitions are common in the medical device industry, with companies like Medtronic, Stryker, and Johnson & Johnson frequently acquiring smaller players.
• The valuation of $5.85 per share in cash reflects the market's assessment of Nevro's value at the time of the merger agreement.
• Comparable transactions in the neuromodulation space would need to be analyzed to determine if this valuation is above or below industry averages.

Stakeholder Impact

• Shareholders of Nevro Corp. received $5.85 in cash for each share they held.
• Employees of Nevro Corp. may experience changes as the company integrates into Globus Medical.
• The merger could lead to changes in the availability or pricing of Nevro's products for customers.

Key Dates

Keywords

Merger, Nevro Corp, Globus Medical, Form 4, Beneficial Ownership, Grossman, Director